Reported about 21 hours ago
H.C. Wainwright remains confident that Viking Therapeutics will stand out in the market following Eli Lilly's data on oral GLP-1 treatments for type 2 diabetes. They expect Viking's drug VK2735, which demonstrated significant weight loss and a favorable safety profile in clinical trials, to provide a competitive edge. The firm maintains a Buy rating on Viking with a price target of $102, despite a recent dip in their stock price.
Source: YAHOO